Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edgewise Therapeutics Inc (EWTX) Stock Forecast
Analysts expect Edgewise Therapeutics (EWTX) to earn $7.42 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.89.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.85, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 23.1% |
| Buy | 9 | 69.2% |
| Hold | 1 | 7.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss.
- Fiscal year ending Dec 31, 2026
- $7.42
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.89
- EPS consensus, revenue $8.64M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $7.42 | -$1.50 to $9.19 | 7 | N/A | N/A | 12 |
| Dec 31, 2027 | -$1.89 | -$2.61 to -$1.24 | 11 | $8.64M | N/A | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.52 for the quarter ending Dec 31, 2026 to -$0.44 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.52 | -$0.76 to -$0.14 | 15 |
| Mar 31, 2027 | -$0.44 | -$0.53 to -$0.31 | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 433.8% from $1.39.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $7.42 | $2.27 | $1.38 | $1.38 | $1.39 | +432.4% |
| Fiscal year ending Dec 31, 2027 | -$1.89 | -$1.87 | -$1.82 | -$1.82 | -$1.78 | N/A |
| Quarter ending Mar 31, 2027 | -$0.44 | -$0.51 | -$0.54 | -$0.54 | -$0.55 | N/A |
Frequently Asked Questions About EWTX
What is the EWTX stock forecast?
Consensus analyst estimates put Edgewise Therapeutics's EPS at $7.42 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.
How do analysts rate EWTX stock?
Of 13 analysts covering Edgewise Therapeutics, 3 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from EWTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $7.42, with estimates from -$1.50 to $9.19 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.89, with estimates from -$2.61 to -$1.24 from 11 analysts.
What revenue do analysts expect from Edgewise Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $8.64M.
How many analysts cover EWTX?
13 analysts rate Edgewise Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EWTX pages: Overview, Earnings, Forecast, Financials, Competitors